CA2916458A1 - Virus like particle comprising pd-1 antigen or pd-1 ligand antigen - Google Patents

Virus like particle comprising pd-1 antigen or pd-1 ligand antigen Download PDF

Info

Publication number
CA2916458A1
CA2916458A1 CA2916458A CA2916458A CA2916458A1 CA 2916458 A1 CA2916458 A1 CA 2916458A1 CA 2916458 A CA2916458 A CA 2916458A CA 2916458 A CA2916458 A CA 2916458A CA 2916458 A1 CA2916458 A1 CA 2916458A1
Authority
CA
Canada
Prior art keywords
particle
virus
seq
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2916458A
Other languages
English (en)
French (fr)
Inventor
Wataru Akahata
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VLP Therapeutics Inc
Original Assignee
VLP Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VLP Therapeutics Inc filed Critical VLP Therapeutics Inc
Publication of CA2916458A1 publication Critical patent/CA2916458A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2916458A 2013-07-12 2014-07-11 Virus like particle comprising pd-1 antigen or pd-1 ligand antigen Abandoned CA2916458A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845712P 2013-07-12 2013-07-12
US61/845,712 2013-07-12
PCT/JP2014/069122 WO2015005500A1 (en) 2013-07-12 2014-07-11 Virus like particle comprising pd-1 antigen or pd-1 ligand antigen

Publications (1)

Publication Number Publication Date
CA2916458A1 true CA2916458A1 (en) 2015-01-15

Family

ID=52277262

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2916458A Abandoned CA2916458A1 (en) 2013-07-12 2014-07-11 Virus like particle comprising pd-1 antigen or pd-1 ligand antigen

Country Status (13)

Country Link
US (2) US9637532B2 (OSRAM)
EP (2) EP3019600B1 (OSRAM)
JP (1) JP6557208B2 (OSRAM)
KR (1) KR20160029124A (OSRAM)
CN (1) CN105358683A (OSRAM)
AR (1) AR096885A1 (OSRAM)
AU (1) AU2014288147B2 (OSRAM)
BR (1) BR112016000303A2 (OSRAM)
CA (1) CA2916458A1 (OSRAM)
IL (1) IL243304B (OSRAM)
MX (1) MX364952B (OSRAM)
TW (1) TWI676636B (OSRAM)
WO (1) WO2015005500A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628206A (en) 2012-02-16 2016-03-31 Vlp Therapeutics Llc Virus like particle composition
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
JP6942309B2 (ja) 2014-09-11 2021-09-29 ブイエルピー・セラピューティクス・インコーポレイテッドＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． フラビウイルスウイルス様粒子
CN107530410B (zh) * 2015-03-18 2021-11-09 欧姆尼赛特有限公司 包含经修饰的α病毒表面糖蛋白与肿瘤相关抗原的融合蛋白及其方法
US10166281B2 (en) * 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2018067361A1 (en) * 2016-10-04 2018-04-12 The Curators Of The University Of Missouri Peptides for molecular detection of pd-l1
EP3589312A1 (en) 2017-03-03 2020-01-08 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
US11357842B2 (en) * 2017-03-17 2022-06-14 Vaximm Ag PD-L1 targeting DNA vaccine for cancer immunotherapy
WO2018183488A1 (en) * 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
WO2019153042A1 (en) * 2018-02-07 2019-08-15 Imugene Limited A vaccine composition and uses thereof
EP3762023A4 (en) * 2018-03-05 2021-12-29 New York University Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
FR3078535B1 (fr) * 2018-03-05 2024-02-09 Peptinov Sas Composition vaccinale anti-pd-l1
WO2020071869A1 (ko) * 2018-10-05 2020-04-09 알엔에이진 주식회사 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
WO2020142700A1 (en) * 2019-01-04 2020-07-09 George Mason Research Foundation, Inc. Binding domain mapping and compounds, compositions, complexes, methods, and kits related thereto
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
BR112022005044A2 (pt) * 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
CN111116733B (zh) * 2019-11-28 2021-11-05 广东药科大学 一种靶向程序性死亡受体1和pd-1配体1相互作用界面的抗原肽和纳米抗体
CN115175924A (zh) * 2020-02-26 2022-10-11 港大科桥有限公司 基于pd-1的针对冠状病毒感染的疫苗
CN115867658A (zh) 2020-04-17 2023-03-28 Vlp治疗公司 冠状病毒疫苗
AU2021264216A1 (en) 2020-04-30 2022-11-10 Vlp Therapeutics, Inc. Cytokine immunotherapy
JPWO2024111633A1 (OSRAM) * 2022-11-24 2024-05-30

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
ES2129461T3 (es) 1991-11-16 1999-06-16 Smithkline Beecham Biolog Proteina hibrida entre cs de plasmodium y hbsag.
US5580773A (en) 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
EP0854929A1 (en) 1995-09-27 1998-07-29 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
AU3289199A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Antigen library immunization
DK1210428T3 (en) * 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
US20110262389A1 (en) 2001-02-13 2011-10-27 Mosca Joseph D Tumor-derived Biological Antigen Presenting Particles
EP1390398A2 (en) 2001-05-30 2004-02-25 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
EP1432791B2 (en) 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replicon vector systems
NZ535690A (en) 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
EP1537878B1 (en) 2002-07-03 2010-09-22 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions
EP1583500A4 (en) 2002-11-13 2008-02-13 Us Navy METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES AND PROTEIN IMMUNITY BY PRIMARY IMMUNIZATION WITH ALPHAVIRUS REPLICON VACCINES
EP2290054B1 (en) 2002-12-13 2017-03-29 Alphavax, Inc. Alphavirus particles and methods for preparation
JP5016305B2 (ja) 2003-03-20 2012-09-05 アルファヴァックス，インコーポレイテッド 改良されたアルファウイルスレプリコンおよびヘルパー構築物
US7790181B2 (en) 2003-05-29 2010-09-07 The United States Of America As Represented By The Secretary Of The Army Live attenuated viral vaccines for Eastern Equine Encephalitis virus
CN101151272A (zh) * 2003-12-01 2008-03-26 陶氏环球技术公司 在假单胞菌中生产重组二十面体病毒样颗粒
CA2567254C (en) 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
RS52187B (sr) 2004-10-14 2012-10-31 Crucell Holland B.V. Vakcine za indukciju i stimulaciju imunskog odgovora za malariju
JP4819792B2 (ja) 2005-02-16 2011-11-24 国立大学法人東京工業大学 改変されたウイルスカプシドタンパク質及びその使用
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
JP5093097B2 (ja) 2006-03-03 2012-12-05 小野薬品工業株式会社 細胞表面機能分子の細胞外領域多量体
US7499304B2 (en) 2006-07-31 2009-03-03 Sandisk 3D Llc Systems for high bandwidth one time field-programmable memory
US20100120092A1 (en) 2006-08-30 2010-05-13 Hepgenics Pty Ltd. Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
GB2453155A (en) 2007-09-26 2009-04-01 Rolls Royce Plc Co-axial pipe assembly which supplies oil to a bearing in a gas turbine engine
US20110035004A1 (en) 2007-11-14 2011-02-10 Maxwell G Interfaced medical implant
US9234181B2 (en) 2007-11-26 2016-01-12 Novartis Ag RNA expression cassette and cells for making alphavirus particles
US9353353B2 (en) * 2008-11-26 2016-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles (VLPs) prepared from chikungunya virus structural proteins
ES2752323T3 (es) 2009-09-18 2020-04-06 Fraunhofer Usa Inc Partículas de tipo virus que comprenden proteínas diana fusionadas a proteínas de revestimiento de virus vegetales
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
KR101837219B1 (ko) 2010-07-13 2018-03-09 데이진 가부시키가이샤 탄소섬유다발 및 그 제조 방법, 및 그로부터의 성형품
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
CN103796676B (zh) 2011-06-17 2017-09-12 伯哈拉特生物技术国际有限公司 包含灭活的基孔肯亚病毒株的疫苗组合物
EP2731961A4 (en) 2011-07-12 2015-12-09 Us Government IDENTIFICATION OF A WEST NIL VIRUS CD4 T-CELL EPITOPS AND USE THEREOF
CN102321639B (zh) 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
LT2768524T (lt) * 2011-10-17 2022-07-25 Io Biotech Aps Pd-l1 grindžiama imunoterapija
BR112014009887A2 (pt) 2011-10-25 2017-04-25 Florida Gulf Coast Univ vacinmas e métodos para desenvolvimento de vacina para indução de imunidade a todos os sorotipos de virus da dengue
NZ628206A (en) 2012-02-16 2016-03-31 Vlp Therapeutics Llc Virus like particle composition
BR112014024612A2 (pt) 2012-04-02 2021-06-08 Univ North Carolina Chapel Hill ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
SMT201800368T1 (it) * 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
SG10201709917VA (en) 2013-06-03 2017-12-28 Vlp Therapeutics Llc Malaria vaccine
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
WO2015139784A1 (en) 2014-03-18 2015-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
JP6942309B2 (ja) 2014-09-11 2021-09-29 ブイエルピー・セラピューティクス・インコーポレイテッドＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． フラビウイルスウイルス様粒子
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US20180339038A1 (en) 2015-06-12 2018-11-29 Mie University Human parainfluenza virus type 2 vector and vaccine
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
UA126548C2 (uk) 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US10166281B2 (en) 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2017150683A1 (en) 2016-03-04 2017-09-08 Vlp Therapeutics, Llc Zika virus virus like particle
CN106085974B (zh) 2016-06-07 2019-08-09 博奥生物集团有限公司 一种寨卡病毒假病毒颗粒及其制备方法

Also Published As

Publication number Publication date
CN105358683A (zh) 2016-02-24
EP3019600A1 (en) 2016-05-18
KR20160029124A (ko) 2016-03-14
TWI676636B (zh) 2019-11-11
US9637532B2 (en) 2017-05-02
US20150017194A1 (en) 2015-01-15
EP3019600A4 (en) 2017-04-12
EP3666890A1 (en) 2020-06-17
JP2016526374A (ja) 2016-09-05
MX364952B (es) 2019-05-14
US20170233450A1 (en) 2017-08-17
JP6557208B2 (ja) 2019-08-07
AR096885A1 (es) 2016-02-03
EP3019600B1 (en) 2019-12-25
IL243304A0 (en) 2016-03-31
IL243304B (en) 2020-02-27
AU2014288147B2 (en) 2020-04-09
US10464986B2 (en) 2019-11-05
AU2014288147A1 (en) 2016-01-21
TW201536812A (zh) 2015-10-01
MX2016000381A (es) 2016-09-07
BR112016000303A2 (pt) 2017-12-12
WO2015005500A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
US10464986B2 (en) Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US9969986B2 (en) Virus like particle comprising modified envelope protein E3
US10385101B2 (en) Virus like particle comprising modified envelope protein E3
JP6734651B2 (ja) マラリアワクチン
MX2014009916A (es) Composicion de particula tipo virus.
JP2015508648A5 (OSRAM)
US10166281B2 (en) Method and composition for modulating immune response
CN117222734A (zh) 靶向半乳凝素的免疫疗法
WO2025146159A1 (zh) 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用
OA17590A (en) Malaria Vaccine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190708

FZDE Discontinued

Effective date: 20211229